Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study
Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients trea...
Gespeichert in:
Veröffentlicht in: | Allergy and asthma proceedings 2025-01, Vol.46 (1), p.45-51 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 51 |
---|---|
container_issue | 1 |
container_start_page | 45 |
container_title | Allergy and asthma proceedings |
container_volume | 46 |
creator | Papaioannou, Andriana I. Kallieri, Maria Zervas, Eleftherios Fouka, Evangelia Porpodis, Konstantinos Hadji Mitrova, Marija Tzortzaki, Eleni Makris, Michael Ntakoula, Maria Lyberopoulos, Panagiotis Dimakou, Katerina Koukidou, Sofia Ampelioti, Sevasti Papaporfyriou, Anastasia Katsoulis, Konstantinos Kipourou, Maria Rovina, Nikoletta Antoniou, Katerina Vittorakis, Stylianos Bakakos, Petros Steiropoulos, Paschalis Markopoulou, Katerina Avarlis, Panteleimon Papanikolaou, Ιlias C. Markatos, Miltiadis Gaki, Eleni Samitas, Konstantinos Glynos, Konstantinos Papiris, Spyros A. Papakosta, Despoina Tzanakis, Nikolaos Gaga, Mina Kostikas, Konstantinos Loukides, Stelios |
description | Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical
remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma
exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after
12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose
of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and
used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9%
versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor
that affects remission and relapse.Clinical trial NCT04084613, www.clinical trials.gov |
doi_str_mv | 10.2500/aap.2025.46.240084 |
format | Article |
fullrecord | <record><control><sourceid>proquest_ingen</sourceid><recordid>TN_cdi_proquest_miscellaneous_3150523059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>ocean/aap/2025/00000046/00000001/art00011</ingid><sourcerecordid>3150523059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</originalsourceid><addsrcrecordid>eNp1kkGL1DAUx4so7rr6BTxIwIuXji9N2mm9DcOqCwOK6Dmk6ctMljapSbrLLPjdTaejC4K5vBB-7_dI_smy1xRWRQnwXspxVUBRrni1KjhAzZ9kl7RkTV4x4E_THuo6LzktLrIXIdwCUM6q6nl2wZo1p2wNl9mvbW-sUbInHgcTgnGWGEtGGQ3aGMi9iQcS8A49EnTBWDceTG8UkSEeBkmiRxmxW7gBR9ebh2mQ7QeyIaMLMT-4xFrZH4MJxGny7Xp3sz9EEuLUHV9mz7TsA74616vsx8fr79vP-e7Lp5vtZperoqwhb3UHqlZNp7EsmWYV57RBbGtgHFDjGipWJ1KlI011J3nFqKa0Uaqiba3YVfZu8Y7e_ZwwRJHuqrDvpUU3BcFoCWXBoGwS-vYf9NZNPl3gRKXBUFBIVLFQyrsQPGoxejNIfxQUxByOSOGIORzBK7GEk5renNVTO2D3t-VPGgnYLICx-_T68nG0UyjtoxNOK5mXDVAhfZwrTY6v_3EYddbM32L-FeKOV5aejECTAzgD0aGWUx9FlF7sH0RIyt9mZLsu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3154410210</pqid></control><display><type>article</type><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</creator><creatorcontrib>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</creatorcontrib><description>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical
remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma
exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after
12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose
of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and
used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9%
versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor
that affects remission and relapse.Clinical trial NCT04084613, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov">www.clinical trials.gov</ext-link></description><identifier>ISSN: 1088-5412</identifier><identifier>ISSN: 1539-6304</identifier><identifier>EISSN: 1539-6304</identifier><identifier>DOI: 10.2500/aap.2025.46.240084</identifier><identifier>PMID: 39741370</identifier><language>eng</language><publisher>United States: OceanSide Publications, Inc</publisher><subject>Adult ; Aged ; Anti-Asthmatic Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Asthma - diagnosis ; Asthma - drug therapy ; Biological effects ; Clinical trials ; Corticoids ; Corticosteroids ; Female ; Gastroesophageal reflux ; Humans ; Key Words: Clinical Remission ; Leukocytes (eosinophilic) ; Male ; Mepolizumab ; Middle Aged ; Monoclonal antibodies ; Predictors Of Remission And Relapse ; Real World ; Regression analysis ; Relapse ; Relight Study ; Remission ; Remission (Medicine) ; Remission Induction ; Respiratory function ; Responders ; Severe Eosinophilic Asthma ; Severity of Illness Index ; Super-Responders ; Sustained Remission ; Treatment Outcome</subject><ispartof>Allergy and asthma proceedings, 2025-01, Vol.46 (1), p.45-51</ispartof><rights>Copyright OceanSide Publications 2025</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39741370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papaioannou, Andriana I.</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Zervas, Eleftherios</creatorcontrib><creatorcontrib>Fouka, Evangelia</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Hadji Mitrova, Marija</creatorcontrib><creatorcontrib>Tzortzaki, Eleni</creatorcontrib><creatorcontrib>Makris, Michael</creatorcontrib><creatorcontrib>Ntakoula, Maria</creatorcontrib><creatorcontrib>Lyberopoulos, Panagiotis</creatorcontrib><creatorcontrib>Dimakou, Katerina</creatorcontrib><creatorcontrib>Koukidou, Sofia</creatorcontrib><creatorcontrib>Ampelioti, Sevasti</creatorcontrib><creatorcontrib>Papaporfyriou, Anastasia</creatorcontrib><creatorcontrib>Katsoulis, Konstantinos</creatorcontrib><creatorcontrib>Kipourou, Maria</creatorcontrib><creatorcontrib>Rovina, Nikoletta</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Vittorakis, Stylianos</creatorcontrib><creatorcontrib>Bakakos, Petros</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Markopoulou, Katerina</creatorcontrib><creatorcontrib>Avarlis, Panteleimon</creatorcontrib><creatorcontrib>Papanikolaou, Ιlias C.</creatorcontrib><creatorcontrib>Markatos, Miltiadis</creatorcontrib><creatorcontrib>Gaki, Eleni</creatorcontrib><creatorcontrib>Samitas, Konstantinos</creatorcontrib><creatorcontrib>Glynos, Konstantinos</creatorcontrib><creatorcontrib>Papiris, Spyros A.</creatorcontrib><creatorcontrib>Papakosta, Despoina</creatorcontrib><creatorcontrib>Tzanakis, Nikolaos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><title>Allergy and asthma proceedings</title><addtitle>Allergy Asthma Proc</addtitle><description>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical
remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma
exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after
12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose
of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and
used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9%
versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor
that affects remission and relapse.Clinical trial NCT04084613, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov">www.clinical trials.gov</ext-link></description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - drug therapy</subject><subject>Biological effects</subject><subject>Clinical trials</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Female</subject><subject>Gastroesophageal reflux</subject><subject>Humans</subject><subject>Key Words: Clinical Remission</subject><subject>Leukocytes (eosinophilic)</subject><subject>Male</subject><subject>Mepolizumab</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Predictors Of Remission And Relapse</subject><subject>Real World</subject><subject>Regression analysis</subject><subject>Relapse</subject><subject>Relight Study</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Respiratory function</subject><subject>Responders</subject><subject>Severe Eosinophilic Asthma</subject><subject>Severity of Illness Index</subject><subject>Super-Responders</subject><subject>Sustained Remission</subject><subject>Treatment Outcome</subject><issn>1088-5412</issn><issn>1539-6304</issn><issn>1539-6304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kkGL1DAUx4so7rr6BTxIwIuXji9N2mm9DcOqCwOK6Dmk6ctMljapSbrLLPjdTaejC4K5vBB-7_dI_smy1xRWRQnwXspxVUBRrni1KjhAzZ9kl7RkTV4x4E_THuo6LzktLrIXIdwCUM6q6nl2wZo1p2wNl9mvbW-sUbInHgcTgnGWGEtGGQ3aGMi9iQcS8A49EnTBWDceTG8UkSEeBkmiRxmxW7gBR9ebh2mQ7QeyIaMLMT-4xFrZH4MJxGny7Xp3sz9EEuLUHV9mz7TsA74616vsx8fr79vP-e7Lp5vtZperoqwhb3UHqlZNp7EsmWYV57RBbGtgHFDjGipWJ1KlI011J3nFqKa0Uaqiba3YVfZu8Y7e_ZwwRJHuqrDvpUU3BcFoCWXBoGwS-vYf9NZNPl3gRKXBUFBIVLFQyrsQPGoxejNIfxQUxByOSOGIORzBK7GEk5renNVTO2D3t-VPGgnYLICx-_T68nG0UyjtoxNOK5mXDVAhfZwrTY6v_3EYddbM32L-FeKOV5aejECTAzgD0aGWUx9FlF7sH0RIyt9mZLsu</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Papaioannou, Andriana I.</creator><creator>Kallieri, Maria</creator><creator>Zervas, Eleftherios</creator><creator>Fouka, Evangelia</creator><creator>Porpodis, Konstantinos</creator><creator>Hadji Mitrova, Marija</creator><creator>Tzortzaki, Eleni</creator><creator>Makris, Michael</creator><creator>Ntakoula, Maria</creator><creator>Lyberopoulos, Panagiotis</creator><creator>Dimakou, Katerina</creator><creator>Koukidou, Sofia</creator><creator>Ampelioti, Sevasti</creator><creator>Papaporfyriou, Anastasia</creator><creator>Katsoulis, Konstantinos</creator><creator>Kipourou, Maria</creator><creator>Rovina, Nikoletta</creator><creator>Antoniou, Katerina</creator><creator>Vittorakis, Stylianos</creator><creator>Bakakos, Petros</creator><creator>Steiropoulos, Paschalis</creator><creator>Markopoulou, Katerina</creator><creator>Avarlis, Panteleimon</creator><creator>Papanikolaou, Ιlias C.</creator><creator>Markatos, Miltiadis</creator><creator>Gaki, Eleni</creator><creator>Samitas, Konstantinos</creator><creator>Glynos, Konstantinos</creator><creator>Papiris, Spyros A.</creator><creator>Papakosta, Despoina</creator><creator>Tzanakis, Nikolaos</creator><creator>Gaga, Mina</creator><creator>Kostikas, Konstantinos</creator><creator>Loukides, Stelios</creator><general>OceanSide Publications, Inc</general><general>OceanSide Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20250101</creationdate><title>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</title><author>Papaioannou, Andriana I. ; Kallieri, Maria ; Zervas, Eleftherios ; Fouka, Evangelia ; Porpodis, Konstantinos ; Hadji Mitrova, Marija ; Tzortzaki, Eleni ; Makris, Michael ; Ntakoula, Maria ; Lyberopoulos, Panagiotis ; Dimakou, Katerina ; Koukidou, Sofia ; Ampelioti, Sevasti ; Papaporfyriou, Anastasia ; Katsoulis, Konstantinos ; Kipourou, Maria ; Rovina, Nikoletta ; Antoniou, Katerina ; Vittorakis, Stylianos ; Bakakos, Petros ; Steiropoulos, Paschalis ; Markopoulou, Katerina ; Avarlis, Panteleimon ; Papanikolaou, Ιlias C. ; Markatos, Miltiadis ; Gaki, Eleni ; Samitas, Konstantinos ; Glynos, Konstantinos ; Papiris, Spyros A. ; Papakosta, Despoina ; Tzanakis, Nikolaos ; Gaga, Mina ; Kostikas, Konstantinos ; Loukides, Stelios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2580-bfd0c8c9dfe553f364419eeb80340efe70638258ceb8f1fda4631f119cc61b8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - drug therapy</topic><topic>Biological effects</topic><topic>Clinical trials</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Female</topic><topic>Gastroesophageal reflux</topic><topic>Humans</topic><topic>Key Words: Clinical Remission</topic><topic>Leukocytes (eosinophilic)</topic><topic>Male</topic><topic>Mepolizumab</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Predictors Of Remission And Relapse</topic><topic>Real World</topic><topic>Regression analysis</topic><topic>Relapse</topic><topic>Relight Study</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Respiratory function</topic><topic>Responders</topic><topic>Severe Eosinophilic Asthma</topic><topic>Severity of Illness Index</topic><topic>Super-Responders</topic><topic>Sustained Remission</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papaioannou, Andriana I.</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Zervas, Eleftherios</creatorcontrib><creatorcontrib>Fouka, Evangelia</creatorcontrib><creatorcontrib>Porpodis, Konstantinos</creatorcontrib><creatorcontrib>Hadji Mitrova, Marija</creatorcontrib><creatorcontrib>Tzortzaki, Eleni</creatorcontrib><creatorcontrib>Makris, Michael</creatorcontrib><creatorcontrib>Ntakoula, Maria</creatorcontrib><creatorcontrib>Lyberopoulos, Panagiotis</creatorcontrib><creatorcontrib>Dimakou, Katerina</creatorcontrib><creatorcontrib>Koukidou, Sofia</creatorcontrib><creatorcontrib>Ampelioti, Sevasti</creatorcontrib><creatorcontrib>Papaporfyriou, Anastasia</creatorcontrib><creatorcontrib>Katsoulis, Konstantinos</creatorcontrib><creatorcontrib>Kipourou, Maria</creatorcontrib><creatorcontrib>Rovina, Nikoletta</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Vittorakis, Stylianos</creatorcontrib><creatorcontrib>Bakakos, Petros</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Markopoulou, Katerina</creatorcontrib><creatorcontrib>Avarlis, Panteleimon</creatorcontrib><creatorcontrib>Papanikolaou, Ιlias C.</creatorcontrib><creatorcontrib>Markatos, Miltiadis</creatorcontrib><creatorcontrib>Gaki, Eleni</creatorcontrib><creatorcontrib>Samitas, Konstantinos</creatorcontrib><creatorcontrib>Glynos, Konstantinos</creatorcontrib><creatorcontrib>Papiris, Spyros A.</creatorcontrib><creatorcontrib>Papakosta, Despoina</creatorcontrib><creatorcontrib>Tzanakis, Nikolaos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Allergy and asthma proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papaioannou, Andriana I.</au><au>Kallieri, Maria</au><au>Zervas, Eleftherios</au><au>Fouka, Evangelia</au><au>Porpodis, Konstantinos</au><au>Hadji Mitrova, Marija</au><au>Tzortzaki, Eleni</au><au>Makris, Michael</au><au>Ntakoula, Maria</au><au>Lyberopoulos, Panagiotis</au><au>Dimakou, Katerina</au><au>Koukidou, Sofia</au><au>Ampelioti, Sevasti</au><au>Papaporfyriou, Anastasia</au><au>Katsoulis, Konstantinos</au><au>Kipourou, Maria</au><au>Rovina, Nikoletta</au><au>Antoniou, Katerina</au><au>Vittorakis, Stylianos</au><au>Bakakos, Petros</au><au>Steiropoulos, Paschalis</au><au>Markopoulou, Katerina</au><au>Avarlis, Panteleimon</au><au>Papanikolaou, Ιlias C.</au><au>Markatos, Miltiadis</au><au>Gaki, Eleni</au><au>Samitas, Konstantinos</au><au>Glynos, Konstantinos</au><au>Papiris, Spyros A.</au><au>Papakosta, Despoina</au><au>Tzanakis, Nikolaos</au><au>Gaga, Mina</au><au>Kostikas, Konstantinos</au><au>Loukides, Stelios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study</atitle><jtitle>Allergy and asthma proceedings</jtitle><addtitle>Allergy Asthma Proc</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>46</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>1088-5412</issn><issn>1539-6304</issn><eissn>1539-6304</eissn><abstract>Background: Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. Objective: In this post hoc analysis of the RELIght study, we aimed to evaluate clinical
remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Methods: Clinical remission was defined as the absence of asthma
exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. Results: A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after
12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose
of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and
used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9%
versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. Conclusion: Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor
that affects remission and relapse.Clinical trial NCT04084613, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov">www.clinical trials.gov</ext-link></abstract><cop>United States</cop><pub>OceanSide Publications, Inc</pub><pmid>39741370</pmid><doi>10.2500/aap.2025.46.240084</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1088-5412 |
ispartof | Allergy and asthma proceedings, 2025-01, Vol.46 (1), p.45-51 |
issn | 1088-5412 1539-6304 1539-6304 |
language | eng |
recordid | cdi_proquest_miscellaneous_3150523059 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adult Aged Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - diagnosis Asthma - drug therapy Biological effects Clinical trials Corticoids Corticosteroids Female Gastroesophageal reflux Humans Key Words: Clinical Remission Leukocytes (eosinophilic) Male Mepolizumab Middle Aged Monoclonal antibodies Predictors Of Remission And Relapse Real World Regression analysis Relapse Relight Study Remission Remission (Medicine) Remission Induction Respiratory function Responders Severe Eosinophilic Asthma Severity of Illness Index Super-Responders Sustained Remission Treatment Outcome |
title | Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A08%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_ingen&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20remission%20in%20patients%20with%20severe%20eosinophilic%20asthma%20treated%20with%20mepolizumab:%20A%20post-hoc%20analysis%20of%20RELIght%20study&rft.jtitle=Allergy%20and%20asthma%20proceedings&rft.au=Papaioannou,%20Andriana%20I.&rft.date=2025-01-01&rft.volume=46&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=1088-5412&rft.eissn=1539-6304&rft_id=info:doi/10.2500/aap.2025.46.240084&rft_dat=%3Cproquest_ingen%3E3150523059%3C/proquest_ingen%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3154410210&rft_id=info:pmid/39741370&rft_ingid=ocean/aap/2025/00000046/00000001/art00011&rfr_iscdi=true |